ALB and neoplasm: As summarized in Table 2, encouraged by successful clinical studies, many researchers have developed albumin-binding prodrugs that can selectively release the anticancer drugs by different biomarkers in tumors, with enhanced tumor accumulation via the high affinity to the endogenous albumins.